Daptomycin
- Generic Name
- Daptomycin
- Brand Names
- Cubicin, Dapzura, Daptomycin Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C72H101N17O26
- CAS Number
- 103060-53-3
- Unique Ingredient Identifier
- NWQ5N31VKK
- Background
Daptomycin is a cyclic lipopeptide antibacterial agent with a broad spectrum of activity against Gram-positive bacteria, including methicillin-susceptible and -resistant Staphylococcus aureus (MSSA/MRSA) and vancomycin-resistant Enterococci (VRE). Chemically, daptomycin comprises 13 amino acids, including several non-standard and D-amino acids, with the C-te...
- Indication
Daptomycin is indicated for the treatment of complicated skin and skin structure infections (cSSSI) in patients one year of age and older. It is also indicated for the treatment of Staphylococcus aureus bloodstream infections (bacteremia) in patients one year of age and older, including in adult patients with right-sided infective endocarditis.
...
- Associated Conditions
- Complicated Skin and Skin Structure Infection, Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
- Associated Therapies
- -
IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Sharp HealthCare
- Target Recruit Count
- 40
- Registration Number
- NCT02660346
- Locations
- 🇺🇸
Sharp Grossmont Hospital, La Mesa, California, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
The Pharmacokinetics/Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock
- Conditions
- Interventions
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- Zhongda Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT02508350
- Locations
- 🇨🇳
Zhongda hospital, Southeast University, Nanjing, Jiangsu, China
Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- University of Zurich
- Registration Number
- NCT02241941
- Locations
- 🇨🇭
University Hospital Zurich, Zurich, Switzerland
A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial
- Conditions
- Interventions
- First Posted Date
- 2014-08-04
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Cumberland Pharmaceuticals
- Target Recruit Count
- 121
- Registration Number
- NCT02208063
- Locations
- 🇺🇸
Remington-Davis Clinical Research, Columbus, Ohio, United States
Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2016-10-11
- Lead Sponsor
- Poitiers University Hospital
- Registration Number
- NCT02142075
- Locations
- 🇫🇷
Lasocki S, University Hospital of Angers, Angers, France
🇫🇷Seguin P, University Hospital of Rennes, Rennes, France
🇫🇷Asehnoune K, University Hospital of Nantes, Nantes, France
Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2016-12-12
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 12
- Registration Number
- NCT02097953
- Locations
- 🇺🇸
University of Utah, Salt Lake City, Utah, United States
Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections
- Conditions
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2018-09-26
- Lead Sponsor
- Cellceutix Corporation
- Target Recruit Count
- 215
- Registration Number
- NCT02052388
- Locations
- 🇺🇸
eStudy Site, Las Vegas, Nevada, United States
Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia
- Conditions
- Interventions
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT01975662
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
- Conditions
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2018-08-28
- Target Recruit Count
- 149
- Registration Number
- NCT01922011
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Target Recruit Count
- 215
- Registration Number
- NCT01792804
- Locations
- 🇳🇱
Amsterdam, Amsterdam, Netherlands
🇳🇱Tilburg, Tilburg, Netherlands
🇳🇱Diakonessenhuis Utrecht, Utrecht, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.